HC Wainwright & Co. Maintains Buy on Oncternal Therapeutics, Lowers Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Oncternal Therapeutics (NASDAQ:ONCT) but has lowered the price target from $19 to $18.
August 12, 2024 | 9:52 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Oncternal Therapeutics but has lowered the price target from $19 to $18.
The maintained Buy rating suggests continued confidence in the stock, but the lowered price target indicates a slightly less optimistic outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100